Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum

American Journal of Surgery

Volumn 176, Issue 6, 1998, Pages 642-647

  Richter, Konrad K ^a   Fink, Louis M ^a   Hughes, Bradley M ^a   Shmaysani, Hasan M ^a   Sung, Ching Ching ^a   Hauer Jensen, Martin ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ADULT; AGED; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION INJURY; RECTUM CANCER; RECTUM RESECTION;

EID: 0032414396     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00280-3     Document Type: Conference Paper

References (23)

1. 1. Richter KK, Fink LM, Hughes BM, et al. Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy? Radiother Oncol. 1997;44:65-71.
2. 2. Richter KK, Langberg CW, Sung C-C, Hauer-Jensen M. Increased transforming growth factor β (TGF-β) immunoreactivity is independently associated with chronic injury in both consequential and primary radiation enteropathy. Int J Radiat Oncol Biol Phys. 1997;39:187-195.
3. 3. Richter KK, Sung C-C, Langberg CW, Hauer-Jensen M. Association of transforming growth factor β (TGF-β) immunoreactivity with specific histopathologic lesions in subacute and chronic experimental radiation enteropathy. Radiother Oncol. 1996;39:201-302.
4. 4. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. NEJM. 1991;324:1-8.
5. 5. Mulcahy HE, Duffy MJ, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 1994;344:583-584.
6. 6. Sier CFM, Fellbaum C, Verspaget HW, et al. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology. 1991;19:231-237.
7. 7. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood. 1990;75:329-336.
8. 8. Wang J, Richter KK, Sung C-C, Hauer-Jensen M. Association of chronic endothelial dysfunction with sustained transforming growth factot-β (TGF-β) overexpression and progression of experimental radiation enteropathy. Radiation Res Soc. 1997;45:194.
9. 9. Langberg CW, Hauer-Jensen M, Sung C-C, Kane CJM. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol. 1994;32:29-36.
10. 10. Canney PA, Dean S. Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy? Br J Radiol. 1990;63:620-623.
11. 11. Lahm H. Role of transforming growth factor β in colorectal cancer. Growth Factors. 1993;9:1-9.
12. 12. Ueki N, Nakazato M, Ohkawa T, et al. Excessive production of transforming growth factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta. 1992;1137:189-196.
13. 13. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370:341-347.
14. 14. Friedman E, Gold LI, Klimstra D, et al. High levels of transforming growth factor β1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomark Prevent. 1995;4: 549-554.
15. 15. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375-382.
16. 16. Kong F-M, Anscher MS, Murase T, et al. Elevated plasma transforming growth factor beta1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 1995;222: 155-162.
17. 17. Li XF, Takiuchi H, Zou JP, et al. Transforming growth factor-β (TGF-β)-mediated immunosuppression in the tumor-hearing state: enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn/J Cancer Res. 1993;84:315-325.
18. 18. Samuel SK, Hurta RAR, Kondaiah P, et al. Autocrine induction of tumor protease production and invasion by a metallothionine-regulated TGF-β1. EMBO J. 1992;11:1599-1605.
19. 19. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL. Regulation of intestinal epithelial growth by transforming growth factor type β. Proc Natl Acad Sci USA. 1989;86:1578-1582.
20. 20. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336-1338.
21. 21. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991;138:1059-1067.
22. 22. Wilhelm S, Wilhelm O, Schmitt M, Graeff H. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex. Biol Chem Hoppe-Seyler. 1994;375:603-608.
23. 23. Nunes I, Munger JS, Harpel JG, et al. Structure and activation of the large latent transforming growth factor-beta complex. Int J Obes Relat Metab Disord. 1996;20(suppl 3):S4-8.